How big is Acutus Medical, Inc.?

As of Jun 18, Acutus Medical, Inc. has a market capitalization of 0.07 million and reported net sales of 20.15 million with a net profit of -4.55 million over the last four quarters. Shareholder's funds are at -11.59 million, and total assets amount to 28.65 million.

As of Jun 18, Acutus Medical, Inc. has a market capitalization of 0.07 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 20.15 million, while the sum of net profit for the same period is -4.55 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -11.59 million, and the total assets amount to 28.65 million.

What does Acutus Medical, Inc. do?

Acutus Medical, Inc. is a micro-cap company specializing in arrhythmia management by designing and marketing tools for catheter-based ablation procedures. As of December 2024, it reported net sales of $7 million and a net profit of -$1 million.

Overview:<BR>Acutus Medical, Inc. is an arrhythmia management company that designs, manufactures, and markets tools for catheter-based ablation procedures, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Million (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Dec 2024) <BR>Market cap: USD 0.07 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 0.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.68 <BR>Return on Equity: -0.01% <BR>Price to Book: -0.01 <BR><BR>Contact Details:<BR>Address: 2210 Faraday Ave Ste 100, CARLSBAD CA: 92008-7225 <BR>Tel: 1 442 2326144 <BR>Fax: 1 858 6732274 <BR>Website: http://www.acutusmedical.com/

Should I buy, sell or hold Acutus Medical, Inc.?

Who are in the management team of Acutus Medical, Inc.?

As of March 2022, the management team of Acutus Medical, Inc. includes Executive Chairman R. Scott Huennekens, President and CEO Vince Burgess, and several Independent Directors: Dr. David Bonita, Dr. Andrew ElBardissi, Mr. Jim Hinrichs, Dr. Shahzad Malik, and Dr. Shaden Marzouk. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Acutus Medical, Inc. includes the following individuals:<BR><BR>- Mr. R. Scott Huennekens, who serves as the Executive Chairman of the Board.<BR>- Mr. Vince Burgess, who is the President, Chief Executive Officer, and Director.<BR>- Dr. David Bonita, who is an Independent Director.<BR>- Dr. Andrew ElBardissi, who is also an Independent Director.<BR>- Mr. Jim Hinrichs, serving as an Independent Director.<BR>- Dr. Shahzad Malik, who is an Independent Director.<BR>- Dr. Shaden Marzouk, who is an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Is Acutus Medical, Inc. overvalued or undervalued?

As of November 12, 2020, Acutus Medical, Inc. is considered overvalued and risky due to negative financial metrics, including a P/E ratio of 0 and a year-to-date return of -99.27%, significantly underperforming the S&P 500's 12.22% return.

As of 12 November 2020, Acutus Medical, Inc. moved from a grade of does not qualify to risky, indicating a significant deterioration in its valuation outlook. The company appears to be overvalued given its negative financial metrics, including a P/E ratio of 0, a Price to Book Value of -0.01, and an EV to EBITDA of -3.84. Comparatively, peers such as LENSAR, Inc. and NeuroOne Medical Technologies Corp. exhibit similarly risky valuations with P/E ratios of -10.55 and -6.96, respectively.<BR><BR>The stock has underperformed significantly against the S&P 500, with a year-to-date return of -99.27% compared to the S&P 500's positive return of 12.22%. This stark contrast reinforces the notion that Acutus Medical, Inc. is overvalued in its current state.

Is Acutus Medical, Inc. technically bullish or bearish?

As of July 21, 2025, Acutus Medical, Inc. shows a mildly bearish trend with mixed technical indicators, including mildly bullish MACD signals but a bearish monthly RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -99.27%.

As of 21 July 2025, the technical trend for Acutus Medical, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is also mildly bullish. However, the monthly RSI is bearish, and the daily moving averages are mildly bearish. The KST shows a mildly bullish trend on the weekly but is bearish on the monthly. Both the Bollinger Bands and Dow Theory reflect a sideways trend with no clear direction. <BR><BR>In terms of performance, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -99.27% compared to the S&P 500's 12.22%. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals from MACD and moving averages.